Second-line antiviral (for chronic hepatitis B infection) therapies for managing treatment failure. Among people with evidence of treatment failure due to confirmed or suspected antiviral resistance (based on history of previous exposure or primary non-response) to lamivudine, entecavir, adefovir or telbivudine, switching to tenofovir disoproxil fumarate is recommended. Tenofovir alafenamide may be considered as an alternate regimen, if available